Home » Stocks » SNY

Sanofi S.A. (SNY)

Stock Price: $53.80 USD 0.02 (0.04%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $53.44 -0.36 (-0.67%) Jun 11, 4:57 PM
Market Cap 135.34B
Revenue (ttm) 45.57B
Net Income (ttm) 15.02B
Shares Out 2.50B
EPS (ttm) 5.86
PE Ratio 9.18
Forward PE 14.25
Dividend $3.20
Dividend Yield 5.95%
Trading Day June 11
Last Price $53.80
Previous Close $53.78
Change ($) 0.02
Change (%) 0.04%
Day's Open 53.85
Day's Range 53.51 - 53.91
Day's Volume 872,656
52-Week Range 43.13 - 54.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Sanofi SA's (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This rare disorder can cause severe anemia without ...

2 days ago - Benzinga

Sanofi CEO on breakthroughs in cancer research, COVID-19 vaccine development, and drug pricing

YouTube video

Sanofi CEO Paul Hudson joins Yahoo Finance's Anjalee Khemlani to discuss the company's cancer research, COVID-19 vaccine efforts, and drug pricing. Watch the 2021 Berkshire Hathaway Annual Shareholders ...

1 week ago - Yahoo Finance

Sanofi SA (NASDAQ: SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast cancer. The Breast International Group (BIG), the European Organizat...

1 week ago - Benzinga

PARIS, June 4, 2021 /PRNewswire/ -- Sanofi is partnering with leading groups delivering practice-changing breast cancer research, the Breast International Group (BIG), the European Organization for Rese...

1 week ago - PRNewsWire

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on ...

Other stocks mentioned: OCGN, VALN, ARCT, CVAC, NVAX, RDY
1 week ago - InvestorPlace

Sanofi l aunches € 3 million Planet Mobilization f und to support employees' environmental projects

1 week ago - GlobeNewsWire

Let's take a look at some top coronavirus vaccine stories of May and the possible impact they can have on biotech ETFs.

Other stocks mentioned: AZN, BBH, BNTX, BTEC, CVAC, FBT, IBB ...
1 week ago - Zacks Investment Research

Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.

1 week ago - Zacks Investment Research

Sanofi SA (NASDAQ: SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile of venglustat remains consistent with previousl...

1 week ago - Benzinga

Sanofi provides update on venglustat clinical program

1 week ago - GlobeNewsWire

Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.

Other stocks mentioned: GSK
2 weeks ago - Zacks Investment Research

One part of the trial will test the vaccine against the South African variant of the virus.

Other stocks mentioned: GSK
2 weeks ago - Forbes

Sanofi and GSK initiate global Phase 3 clin i cal efficacy study of COVID-19 vaccine candidate

Other stocks mentioned: GSK
2 weeks ago - GlobeNewsWire

Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA (NASDAQ: SNY) and China's Walvax soon. Mexico's health regulator Cofepris approv...

2 weeks ago - Benzinga

Regeneron (REGN) and Sanofi's (SNY) Libtayo gets positive CHMP opinion for two additional indications.

Other stocks mentioned: REGN
2 weeks ago - Zacks Investment Research

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Libtayo...

Other stocks mentioned: REGN
2 weeks ago - Benzinga

It's hard to beat dividend-paying stocks -- they offer reliable income as well as stock-price appreciation.

Other stocks mentioned: IRM, MCD
3 weeks ago - The Motley Fool

Sanofi SA (NASDAQ: SNY) revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader. Data will be presented at the 2021 American Society of ...

3 weeks ago - Benzinga

These are two cheap stocks in an overvalued market.

Other stocks mentioned: GSK
3 weeks ago - The Motley Fool

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting

3 weeks ago - GlobeNewsWire

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

Other stocks mentioned: ALKS, BIIB, BMY, BPMC, MYOV, PRVB, VRTX
3 weeks ago - Kiplinger

Sanofi: Our vaccine could serve as an excellent booster shot

YouTube video

Thomas Triomphe, EVP at Sanofi Pasteur, discusses preliminary data from a Phase 2 trial for the drugmaker's Covid-19 vaccine developed in partnership with GlaxoSmithKline.

3 weeks ago - CNBC International TV

Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the co...

3 weeks ago - Zacks Investment Research

Not convinced IP waiver rights will accelerate vaccine access: Sanofi Pasteur EVP

YouTube video

Thomas Triomphe discusses the results of its Covid-19 vaccine trial and the issue of IP wavier rights.

3 weeks ago - CNBC International TV

Sanofi (EPA: SAN) said on Monday its candidate COVID-19 vaccine that it developed with Britain's GlaxoSmithKline (LON: GSK) showed promising results in early-stage clinical trials, paving the way to mov...

3 weeks ago - Invezz

GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market react...

Other stocks mentioned: GSK
3 weeks ago - Proactive Investors

GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market react...

Other stocks mentioned: GSK
3 weeks ago - Proactive Investors

A Phase 3 trial to test the vaccine's efficacy is expected to start in a matter of weeks, with the vaccine showing potential to be a booster shot.

Other stocks mentioned: GSK
3 weeks ago - Forbes

Sanofi and GSK see positive interim results for their Covid vaccine in trials

YouTube video

CNBC's Charlotte Reed reports on the Sanofi-GSK Covid-19 vaccine showing a "strong immune response" in phase 2 trials.

Other stocks mentioned: GSK
3 weeks ago - CNBC International TV

Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of their COVID-19 vaccine, raising hopes it could join the fi...

3 weeks ago - Benzinga

News will offer some some relief for GSK chief Emma Walmsley, who has been under pressure from investor

Other stocks mentioned: GSK
3 weeks ago - The Guardian

GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion f...

Other stocks mentioned: GSK
3 weeks ago - Proactive Investors

GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion f...

Other stocks mentioned: GSK
3 weeks ago - Proactive Investors

You might want to add this international blue-chip stock to your portfolio.

1 month ago - The Motley Fool

It signals a big push toward curing a neurological disease with a massive market.

Other stocks mentioned: DNLI, LLY, MRNA, SAVA
1 month ago - The Motley Fool

The companies have a promising RSV candidate.

Other stocks mentioned: AZN
1 month ago - The Motley Fool

PARIS and PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.

1 month ago - PRNewsWire

Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Earnings...

1 month ago - Benzinga

Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.

1 month ago - Zacks Investment Research

Covid vaccine will be available by the end of 2021, says Sanofi CEO

YouTube video

Sanofi CEO Paul Hudson joins "Squawk on the Street" to discuss the company's Q1 results, the development of a vaccine for Covid and more.

1 month ago - CNBC Television

Sanofi's first quarter boosted by eczema treatment and vaccines

YouTube video

CNBC's Charlotte Reed reports on Sanofi's first-quarter results which came in line with expectations, while the French pharmaceutical still works on its delayed Covid-19 vaccines.

1 month ago - CNBC International TV

Sanofi confirmed its 2021 targets after it posted stronger-than-expected first quarter results as sales of its star eczema treatment as well as flu and polio vaccines helped offset a dip in cough and co...

1 month ago - Reuters

As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA) to manufacture its COVID-19 vaccine in the U.S. The agreement ma...

Other stocks mentioned: MRNA
1 month ago - Benzinga

The shots could be geared towards children, new variants or boosters.

Other stocks mentioned: MRNA
1 month ago - Forbes

Sanofi to manufacture up to 200 million doses of Moderna's Covid vaccine

YouTube video

Sanofi says it has entered into an agreement with Moderna to help bottle the company's coronavirus vaccine starting in September 2021. CNBC's Meg Tirrell reports.

Other stocks mentioned: MRNA
1 month ago - CNBC Television

BRIDGEWATER, N.J., April 26, 2021 /PRNewswire/ -- Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s COVID-19 vaccine, supporting the COVID-19 pandemic...

1 month ago - PRNewsWire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces agreement with Sanofi for fill/finish manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Other stocks mentioned: MRNA
1 month ago - Business Wire

Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc's (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respiratory syncyti...

Other stocks mentioned: AZN
1 month ago - Benzinga

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Other stocks mentioned: AMGN, BMY, REGN, REPL, RHHBY
1 month ago - GuruFocus

About SNY

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescriptio... [Read more...]

Industry
Drug Manufacturers-General
CEO
Olivier Brandicourt
Employees
99,412
Stock Exchange
NASDAQ
Ticker Symbol
SNY
Full Company Profile

Financial Performance

In 2020, Sanofi's revenue was 37.37 billion, a decrease of -0.70% compared to the previous year's 37.63 billion. Earnings were 12.31 billion, an increase of 338.85%.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Sanofi stock is "Buy." The 12-month stock price forecast is 63.88, which is an increase of 18.74% from the latest price.

Price Target
$63.88
(18.74% upside)
Analyst Consensus: Buy